The Business Research Company’s Alzheimer’s Disease Diagnostic Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035
LONDON, GREATER LONDON, UNITED KINGDOM, April 28, 2026 /EINPresswire.com/ — “The alzheimer’s disease diagnostic market is characterized by the presence of global in-vitro diagnostics (IVD) companies, advanced imaging solution providers, and specialized biomarker technology developers. Companies are focusing on the development of high-sensitivity biomarker assays, blood-based diagnostic solutions, advanced neuroimaging technologies, AI-enabled diagnostic platforms, and integrated diagnostic workflows to enhance early detection and disease monitoring capabilities. Emphasis on improving diagnostic accuracy, enabling non-invasive and cost-effective testing, accelerating clinical validation, and ensuring regulatory compliance remains central to competitive positioning. Additionally, growing focus on early-stage detection, personalized treatment planning, and integration of diagnostics with therapeutic development is shaping innovation strategies across the market. Understanding the competitive landscape is critical for stakeholders aiming to capitalize on emerging opportunities, technological advancements, and strategic collaborations within the rapidly evolving neurodegenerative disease diagnostics ecosystem.
Which Market Player Is Leading The Alzheimer’s Disease Diagnostic Market?
•According to our research, F. Hoffmann-La Roche Ltd. led global sales in 2024 with a 3% market share. The company’s advanced diagnostic solutions, which are directly involved in the Alzheimer’s disease diagnostic market, provide a comprehensive portfolio of in-vitro diagnostic platforms, biomarker-based assays, molecular diagnostics, and imaging support tools that enable early detection, disease progression monitoring, and precision diagnosis, supporting improved clinical decision-making and patient management across neurological and healthcare settings.
Who Are The Major Players In The Alzheimer’s Disease Diagnostic Market?
Major companies operating in the alzheimer’s disease diagnostic market are F. Hoffmann-La Roche Ltd., Fujirebio Holdings Inc., Siemens Healthineers AG, Quest Diagnostics Incorporated, Sysmex Corporation, GE HealthCare, Quanterix Corporation, Revvity Inc., Koninklijke Philips N.V., DiaSorin S.p.A., Canon Inc., Laboratory Corporation of America Holdings, Hitachi Ltd., Lantheus Holdings Inc., Eisai Co. Ltd., Nipro Corporation, C2N Diagnostics LLC, Alamar Biosciences Inc., Eli Lilly and Company, Randox Laboratories Ltd., ADx Neurosciences NV.
How Concentrated Is The Alzheimer’s Disease Diagnostic Market?
•The market is fairly fragmented, with the top 10 players accounting for 14% of total market revenue in 2024. This level of concentration reflects high technological and regulatory entry barriers, driven by the need for clinically validated biomarkers, stringent regulatory approvals, high R&D investments, and integration of diagnostics with imaging and digital health platforms. Leading players such as F. Hoffmann-La Roche Ltd., Fujirebio Holdings Inc., Siemens Healthineers AG, Quest Diagnostics Incorporated, Sysmex Corporation, GE HealthCare, Quanterix Corporation, Revvity Inc., Koninklijke Philips N.V., and DiaSorin S.p.A. maintain notable market positions through strong diagnostic portfolios, proprietary biomarker technologies, global laboratory networks, and strategic collaborations with research institutions and pharmaceutical companies. As demand for early detection, minimally invasive diagnostics, and precision medicine increases, continuous innovation in biomarker discovery, expansion of blood-based testing, and adoption of AI-driven diagnostic tools are expected to further strengthen the competitive positioning of these companies in the market.
•Leading companies include:
oF. Hoffmann-La Roche Ltd. (3%)
oFujirebio Holdings Inc. (2%)
oSiemens Healthineers AG (1%)
oQuest Diagnostics Incorporated (1%)
oSysmex Corporation (1%)
oGE HealthCare (1%)
oQuanterix Corporation (1%)
oRevvity Inc. (1%)
oKoninklijke Philips N.V. (1%)
oDiaSorin S.p.A. (1%)
Request A Free Sample Of The Alzheimer’s Disease Diagnostic Market Report
https://www.thebusinessresearchcompany.com/sample_request?id=21093&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Who Are The Key Raw Material Suppliers In The Alzheimer’s Disease Diagnostic Market?
•Major raw material suppliers in the alzheimer’s disease diagnostic market include Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Agilent Technologies Inc., Bio-Rad Laboratories Inc., PerkinElmer Inc., Lonza Group AG, Sartorius AG, Promega Corporation, Abcam plc, GenScript Biotech Corporation, and Bio-Techne Corporation.
Who Are The Leading Wholesalers Or Distributors In The Alzheimer’s Disease Diagnostic Market?
•Major wholesalers or distributors in the alzheimer’s disease diagnostic market include McKesson Corporation, Cardinal Health Inc., AmerisourceBergen Corporation, Henry Schein Inc., Owens & Minor Inc., Medline Industries LP, Avantor Inc., VWR International LLC, FFF Enterprises Inc., Anda Inc., and Morris & Dickson Co. LLC.
Who Are The Major End Users Of The Alzheimer’s Disease Diagnostic Market?
•Major end users in the alzheimer’s disease diagnostic market include Quest Diagnostics, Laboratory Corporation of America Holdings, SYNLAB International GmbH, and Sonic Healthcare Limited.
What Are The Major Competitive Trends In The Market?
•Ultra-sensitive blood-based diagnostics are transforming the Alzheimer’s disease diagnostic market by enabling earlier detection, improving diagnostic accuracy, and supporting timely disease management through minimally invasive testing approaches.
•Example: In March 2024, Neurocode USA Inc. launched the ALZpath pTau217 blood test, an ultra-sensitive immunoassay designed to detect low concentrations of phosphorylated tau217 (pTau217) using a commercial high-sensitivity platform.
•Its ability to deliver rapid, accessible, and highly specific biomarker detection enhances early diagnosis, reduces reliance on invasive or costly procedures, and supports improved clinical decision-making and patient outcomes.
Which Strategies Are Companies Adopting To Stay Ahead?
•Expanding multi-biomarker blood panels to enhance risk assessment and enable personalized Alzheimer’s evaluation.
•Introducing tau-targeted blood assays to support early detection and improve diagnostic accuracy.
•Advancing blood-based biomarker tests to enable non-invasive detection and strengthen clinical assessment.
•Deploying FDA-cleared in vitro blood tests to standardize early diagnosis and streamline workflows.
Access The Detailed Alzheimer’s Disease Diagnostic Market Report Here
https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.
Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company“
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
